Investing.com - Biomerieux reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomerieux announced earnings per share of €2.73 on revenue of €924.5M. Analysts polled by Investing.com anticipated EPS of €1.75 on revenue of €905.23M.
Biomerieux shares are down 17% from the beginning of the year, still down 34.26% from its 52 week high of €133.20 set on November 26, 2021. They are under-performing the FTSE 100 which is up 0.61% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings beat by Sanofi on February 4, who reported EPS of €1.38 on revenue of €9.99B, compared to forecasts EPS of €1.34 on revenue of €10.31B.
Ipsen had beat expectations on February 11 with fourth quarter EPS of €7.76 on revenue of €791M, compared to forecast for EPS of €3.39 on revenue of €774.01M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar